2019 was a monumental year for single-cell genomics: from enabling custom DNA panels with AI-driven technology, to partnering with key businesses in the drug development ecosystem, to pioneering research revealing the mechanisms used by rogue cancer cells to evade targeted therapies, the Tapestri Platform has opened up high-impact applications for customers around the world.
Perhaps the most important advancement in Mission Bio’s pursuit for improved cancer therapies is enabling industry-first capability in single-cell multimodal omics: simultaneous detection of DNA mutations and protein expression in a single experiment from the same cell. The ability to correlate the genotype and phenotype of cancer cells directly and without inference gives cancer researchers a transformative understanding of the disease, bringing them ever closer to more effective cures.
Nature has recognized single-cell multimodal omics as the Method of the Year and we are proud that the Tapestri Platform is enabling this for researchers around the world. With the leading platform for single-cell multimodal omics, Mission Bio is on a mission to enable the cancer research community to find cures for cancer.
Happy new year, and we look forward to seeing you in Marco Island.
